NCT00397813 - Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2017

Study Completion Date

March 31, 2018

Conditions

Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromeEssential ThrombocythemiaMyeloproliferative NeoplasmParoxysmal Nocturnal HemoglobinuriaPolycythemia VeraPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary MyelofibrosisRefractory AnemiaRefractory Anemia With Excess BlastsRefractory Anemia With Ring SideroblastsRefractory Cytopenia With Multilineage DysplasiaRefractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts

Interventions

DRUG

Cyclosporine

Given PO

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Mycophenolate Mofetil

Given PO

PROCEDURE

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Undergo transplantation

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo PBSC transplant

RADIATION

Total-Body Irradiation

Undergo TBI

Trial Locations (3)

84143

LDS Hospital, Salt Lake City

98108

Veterans Administration Center-Seattle, Seattle

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER